We report that elevated microRNA-133b (miR-133b) acts as an oncogene in human cervical carcinoma to promote tumorigenesis and metastasis. In situ hybridization confirmed that miR-133b is localized in proliferating human cervical carcinoma cells with levels progressively elevating throughout advancing stages. Cellular studies showed that miR-133b enhances cell proliferation and colony formation by targeting mammalian sterile 20-like kinase 2 (MST2), cell division control protein 42 homolog (CDC42) and ras homolog gene family member A (RHOA), which subsequently results in activation of the tumorigenic protein kinase B alpha (AKT1) and mitogenactivated protein kinase (ERK1 and ERK2, here abbreviated as ERK) signaling pathways. Mouse experiments revealed that upregulation of miR-133b in cervical carcinoma cells strongly promotes both in vivo tumorigenesis and independent metastasis to the mouse lung. The data indicates that upregulation of miR-133b shortens the latency of cervical carcinoma. Together, these findings suggest that miR-133b could be a potent marker for the early onset of cervical carcinoma.
Introduction
Uterine cervical cancer is the second most common cancer in women worldwide with 500 000 new cases annually (Parkin et al., 2005) , and is one of the leading causes of cancer-related deaths in young women (zur Hausen, 2002) . Most squamous cell carcinomas and adenocarcinomas of the stratified epithelium are human papillomavirus (HPV) positive. Although HPV is capable of initiating precancerous development by the disruption of multiple host tumor-suppressor pathways and is the principal factor for predisposition to cancer, additional host cell factors are required for development of the fully transformed malignant phenotype (Burk, 1999) .
Cervical intraepithelial neoplasia (CIN) is a welldefined premalignant phase of cervical cancer, which is classified into three grades with increasing severity: CIN grade 1 (CIN 1), CIN grade 2 (CIN 2) and CIN grade 3 (CIN 3, carcinoma in situ (CIS)). About 70-90% CIN 1 lesions undergo spontaneous regression, whereas the regression rates for CIN 2 and CIN 3 are estimated to be 43% and 30%, respectively (Kahn, 2009) . The reasons for the decreased rate of spontaneous regression are presently unclear. Cellular factors are believed to contribute to the progression of higher CIN phase to CIS phase (Burk, 1999) .
MicroRNAs (miRNAs) are small noncoding singlestranded regulatory RNA-controlling elements that potentially regulate hundreds of target genes, contributing to the combinational regulation of numerous genetic pathways (Lewis et al., 2005) . Altered miRNA expression levels correlate with various cancers and their phenotypes, implying that the deregulation of miRNAs can impinge on tumorigenesis, metastasis and angiogenesis (Garzon et al., 2009 ), yet little is known about the functional targets of many such deregulated miRNAs. As in our previous work (Guo et al., 2008 (Guo et al., , 2011 Tan et al., 2011) we first profiled the deregulation of miRNA expression in cancer tissues, and in this study confirmed highly expressed levels of isoform miR-133b in advanced human cervical carcinoma specimens.
MiR-133 has also been reported to be deregulated in other types of carcinomas (Wong et al., 2008; Crawford et al., 2009; Liu et al., 2009; Hu et al., 2010) , but its roles in the development of these cancers have not been studied. Our in vitro and in vivo functional assays with cervical carcinoma cell lines revealed that miR-133b promotes tumorigenesis and metastasis by enhancing cell proliferation and colony formation capabilities, indicating that miR-133b is an important cellular factor contributing to the progression of cervical cancer.
Results

MiR-133b is increasingly elevated during cervical carcinoma progression
We initially profiled the expression of a panel of miRNAs by microarrays to determine the miRNA genes affected in cervical carcinoma. Twenty differentially expressed miRNAs were identified by significance analysis of microarrays (Tusher et al., 2001) (Figure 1a) . Two previous profiles of miRNAs in cervical carcinomas (Lee et al., 2008; Wang et al., 2008) were compared with our data, yet only three deregulated miRNAs were in common, miR-133 (isoforms miR-133a and miR133b) and miR-127 (Supplementary Figure S1a) . Mammalian miR-133 has two mature isoforms, miR-133a and miR-133b, which differ at a single 3 0 -terminal base, although the pre-miR-133a and -133b sequences are more different (Supplementary Figure S1b) . The other studies did not discriminate between miR-133a and miR-133b in cervical carcinoma tissues. Here, we distinguished the two isoforms by pre-miRNA amplification, and identified isoform miR-133b to be almost exclusively present in cervical carcinomas (Supplementary Figure S1c) . Semiquantitative PCR results revealed that the pre-miR-133b levels in cervical carcinoma tissues were higher than those in normal cervical tissues, indicating the upregulation of miR-133b expression in carcinoma samples (Supplementary Figure S1d ). Subsequently, real-time reverse transcription-PCR (RT-PCR) confirmed the upregulation of miR-133b and miR-127 in cervical carcinomas (Supplementary Figures S1e and f) . Notably, when miR-133b and miR-127 genes were transiently overexpressed independently in epidermoid cervical carcinoma (CaSki) cells (Supplementary Figures S2a and b) , subsequent soft agar colonization assays revealed that elevated miR-133b promotes colony formation, whereas miR-127 has little effect (Supplementary Figure S2c) . Thus, we focused our study on miR-133b.
Sectioned formalin-fixed paraffin-embedded biopsies were examined by real-time RT-PCR, revealing that the median miR-133b levels continuously increased from normal tissues to CIN 2 (4.3-fold), to CIN 3 (5.9-fold) and to invasive carcinoma (7.7-fold), which is statistically significant (Po0.05) (Figure 1b) . In situ hybridization (ISH) of the pathological samples using a digoxigenin-labeled anti-miR-133b locked nucleic acid (LNA) probe confirmed the relative levels and localization of miR-133b in three normal cervical samples, seven CIS samples and five invasive carcinoma samples. A notable elevation of miR-133b levels in six out of seven CIS samples, and the strong elevation in five of five invasive carcinoma specimens were found, compared with normal tissue levels ( Figure 1c) . A weak miR-133b signal was only found in basal cells of normal epithelium, coincident with the proliferation marker Ki-67 (immunohistochemically stained) (Figure 1c ). In contrast, epithelial layers of cervical carcinoma specimens identified by hematoxylin and eosin staining were strongly labeled for miR-133b in the same cell distribution as stained strongly for Ki-67 (Figure 1c) , indicating a marked proliferative capacity associated with the elevated miR-133b. Taken together, this expression variation in dividing cells across multiple cancer stages suggests that elevated amounts of miR-133b are coincident with the progression of human cervical cancer.
Most squamous cervical carcinomas are HPV positive. We used PCR to screen the CIN 3 and invasive cervical carcinoma samples for HPV infection and identified three HPV-negative carcinomas (two squamous cell carcinomas and one adenosquamous carcinoma), which was also confirmed by ISH (Supplementary Figures S3a, b and c and Supplementary Table S1 ). Complementary RT-PCR and ISH assays showed that miR-133b expression was also upregulated in the three carcinoma samples lacking detectible HPV, suggesting that the elevation of miR-133b levels is an event associated with cancer progression in both HPV-positive and HPV-negative cervical carcinomas (Supplementary Figures S3d and e) .
MiR-133b enhances cell proliferation in three-dimensional (3D) cultures and colony formation in soft agar assays We analyzed the expression levels of miR-133b in four different cervical cell lines with different physiological backgrounds ( Figure 2a and Supplementary Table S2) , and manipulated miR-133b expression in these cell lines to explore its role in cervical cancer progression. CaSki and SiHa have a lower relative endogenous miR-133b expression, whereas HeLa and C33A have relatively higher expression. A sponge sequence containing four miR-133b-binding sites was stably expressed in C33A-miR-133b-sponge cells to inhibit the functions of endogenous miR133b ( Supplementary Figures S4a and b) . In addition, stable overexpression of a human miR-133b gene fragment in CaSki-miR-133b and SiHa-miR-133b cell lines greatly enhanced (40-60 fold) the low endogenous levels of miR133b (Supplementary Figure S4c) .
The ISH and immunohistochemistry (IHC) results with cervical tissues (Figure 1c ) indicated that miR-133b is associated with cell proliferation. We used 3D culture to mimic the in vivo proliferation of cervical cells with different stably expressed levels of miR-133b (Shibue and Weinberg, 2009 ). C33A cells, with high endogenous levels of miR-133b, have high rates of cell proliferation, but when miR-133b activity was blocked in C33A-miR-133b-sponge, cell proliferation was inhibited (Figure 2b ). Although in CaSki and SiHa cells with low endogenous miR-133b expression the cell proliferation rates are low, but when miR-133b levels were upregulated cell proliferation was markedly enhanced compared with standard CaSki and SiHa cells (Figure 2d ). The reactions of the different cervical cell lines were fully complementary and show that miR-133b promotes cell proliferation in agreement with the IHC finding that miR-133b colocalizes in proliferating neoplastic cervical cells along with Ki-67, a marker of cell proliferation. The soft agar assay is widely used as an in vitro surrogate measure of the survival and tumorigenic capabilities of tumor cells (Good et al., 1978; Cifone and Fidler, 1980; Singh et al., 2004) . Soft agar assays with the above stable cell lines showed parallel effects. When the activity of miR-133b was blocked in C33A-miR-133b-sponge cells, colony formation was reduced, providing initial evidence that elevated miR-133b may also promote colony formation ( Figure 2c and Supplementary Figure S4d ). In other experiments, when expression levels of miR-133b were upregulated in CaSki-miR-133b and SiHa-miR-133b cells, the observed colony numbers increased, confirming the ability of miR-133b to promote colony formation in different cervical cell backgrounds ( Figure 2e and Supplementary Figure S4e ). These results suggest that elevated miR133b levels in cervical cells would help to promote tumorigenesis in vivo.
MiR-133b promotes in vivo tumorigenesis and metastasis
We examined the in vivo tumorigenic effects of miR133b by s.c. transplanting CaSki-miR-133b cells and control cells into severe combined immuno-deficiency (SCID) mice. The incremental increase in both tumor volume ( Figure 3a ) and mass ( Figure 3b ) was significantly stimulated over time by miR-133b expression, providing further strong evidence that miR-133b promotes tumor growth markedly in vivo. To further test the tumorigenic functions of miR-133b, we overexpressed miR-133b in HK-2 cells, an epithelial cell line immortalized by HPV 16 E6/E7 genes, which were reported to be nontumorigenic (Ryan et al., 1994) (Supplementary Figure S4f) . The results of soft agar assays showed that HK-2-miR-133b cells had greatly enhanced colony formation capability compared with HK-2 cells (Supplementary Figure S4g) . Mouse experiments revealed that 91.7% of mice (11/12) inoculated with HK-2-miR-133b cells formed tumors, whereas only 27.3% of mice (3/11) inoculated with control cells (HK-2-NC) formed tumors (Supplementary Figure S4h) , indicating clearly that miR-133b promotes tumorigenesis. Together, these studies with stable cells suggest that the upregulation of miR-133b levels promotes in vivo tumorigenesis in mice, and reflect the events occurring in human cervical tissues with upregulating levels of miR133b during the progressive development of cervical carcinoma.
To model metastasis, we i.v. injected SiHa-miR-133b cells (and control cells) into SCID mice and examined the time course of the disease. Anatomical results indicated a significant increase in the number of lungmetastatic foci (>30-fold), indicating that miR-133b overexpression in SiHa-miR-133b cells also promotes metastasis formation strongly in vivo (Figures 3c and d and Supplementary Figure S5a) . Histologically-stained lung sections of the SCID mice showed that the clonal foci emerged 4 weeks after i.v. injection, whereas colonies formed by control cells were delayed and emerged only 6 weeks after i.v. injection (Supplementary Overexpression of miR-133b in CaSki and SiHa cells promotes cell proliferation in 3D cultures (d) and colony formation in soft agar assays (e). NC represents stable cell lines constructed using empty vectors as negative control, whereas miR-133b represents stable cell lines constructed using miR-133b-expressing plasmids. MiR-133b-sponge represents stable cell lines constructed by using the plasmid expressing a sponge sequence containing four miR-133b binding sites. *Po0.05. Both of these findings were consistent with the in vitro 3D culture proliferation assays described above, which mimic aspects of the in vivo microenvironment surrounding recently extravasated cancer cells (Shibue and Weinberg, 2009 ). Together, the in vitro cellular assays and in vivo animal assays demonstrate that miR-133b promotes both tumorigenesis and metastasis.
MiR-133b activates AKT1 and ERK signaling pathways We sought to understand the molecular mechanisms underlying the promotion of tumorigenesis and metastasis by miR-133b. The AKT signaling pathway regulates cell survival, apoptosis and motility, and has a central role in tumorigenesis (Testa and Bellacosa, 2001) . The ERK pathway is deregulated in one-third of all human cancer types (Dhillon et al., 2007) , and supporting ERK activity is known as a determinant of metastatic cell growth (Aguirre-Ghiso et al., 2003) . When the endogenous miR-133b in C33A cells was blocked by an miR-133b sponge, levels of phosphorylated AKT1 and ERK were reduced ( Figure 4A ). In confirmation, the overexpression of miR-133b in CaSkimiR-133b cells increased the levels of phosphorylated AKT1 and ERK ( Figure 4A ). Furthermore, when miR133b activity was transiently inhibited in CaSki-miR133b cells by a hairpin miR-133b inhibitor, the activation of AKT1 and ERK by miR-133b was reduced. All three experiments confirm a role of miR133b in the regulation of AKT1 and ERK activities ( Figure 4A ), and link also to the effects of altered miR133b levels and changed cell proliferation, and colony formation capabilities. We then examined the levels of phospho-AKT1 (p-AK T1) and phospho-ERK (p-ERK) phosphoproteins in tissue sections during the development of human cervical carcinomas. ISH and IHC analysis in consecutive pathological dissections showed strong correlations between miR-133b, p-AKT1 and p-ERK levels in cells in all seven carcinoma specimens examined ( Figure 4B ). In contrast, weak miR-133b expression correlated with low p-AKT1 and p-ERK in all three normal specimens examined ( Figure 4B ). Strongly positive p-AKT1 signals were found in both the nucleus and cytoplasm of carcinoma cells ( Figure 4B , panel h), as was p-ERK ( Figure 4B , panel j), however both enzymes were only weakly detected in normal epithelial cells (Figure 4b , panels g and i, respectively), indicating the activation of AKT1 and ERK in carcinoma cells. The activation of p-AKT1 determined here by IHC in carcinoma cells is in good agreement with previously reported findings (Bertelsen et al., 2006; Kohrenhagen et al., 2008) . Notably, this distribution of p-AKT1-positive and p-ERK-positive cells is closely coincident with the distribution of miR-133b-positive cells in carcinoma samples, giving histological support to the relationship between AKT1 and ERK activation and the upregulation of miR-133b in cervical cancer. In normal cervical epithelium, p-AKT1 and p-ERK were restricted to the basal cells located in the basement membrane, which are positive for the proliferation marker Ki-67. Taken together, the various pathological phenomena in histological cervical carcinomas and parallel observations seen with in vitro cell experiments indicate that miR-133b strongly induces activation of AKT1 and ERK signaling pathways, which contribute to the development of cancers, both in situ and at secondary sites. The third panel presents proteins detected in cell lysates from CaSki-miR-133b cells prepared 48 h after transfection with miR133b inhibitor (100 nM) or with control inhibitor. The p-ERK or p-AKT1 levels were determined by the ImageJ software (National Institutes of Health, Bethesda, MD, USA) and normalized to the levels of ERK or AKT1. (B) The concurrence of miR-133b upregulation and corresponding variation of p-AKT1 and p-ERK was confirmed in human cervical specimens by ISH and immunohistochemical assays. NT, normal tissue. Scale bar, 100 mm.
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MiR-133b targets MST2, CDC42 and RHOA We then undertook to identify direct targets through which miR-133b regulates these key cancer-associated signaling pathways. Among the approximately 400 potential targets predicted by TargetScan (Whitehead Institute for Biomedical Research, Cambridge, MA, USA) and PicTar (New York University, New York, NY, USA) programs (Lewis et al., 2003; Krek et al., 2005) , MST2 is an important known tumor suppressor known to effect MAPK and AKT signaling activities in several diseases (Cinar et al., 2007; Mumby, 2007) . MST2 mRNA contains a 3 0 -untranslated region (UTR) partially complementary to miR-133b, which is highly conserved among human, mouse and rat orthologs (Figure 5a ). In reporter assays, the co-transfection of miR-133b with luciferase reporter gene linked to the wild-type 3 0 -UTR of MST2 caused a significant decrease in luciferase activity (Figure 5b ), whereas the substitution of two nucleotides within the seed region effectively interrupted the reduction of luciferase activity by miR133b (Figures 5a and b) . MiR-133b was also overexpressed in CaSki cells with adenoviral vectors to determine whether miR-133b affects the levels of MST2 protein and mRNA. At the mRNA level, a 41% downregulation of MST2 was observed (Figure 5c) . At the protein level, a 62% downregulation of MST2 protein was observed in western blot assays (Figure 5d ). These data indicated that miR-133b may directly target MST2 through both translational repression and degradation of MST2 mRNA (He and Hannon, 2004) .
We also attempted to reexpress MST2 in cell lines to determine whether its ectopic expression could prevent the effects of miR-133b on ERK and AKT1 signaling, but overexpression of MST2 caused cell death (data not shown), suggesting that MST2 may have dominant roles in limiting cell survival. In yet further assays, CaSki cells were transfected with a specific small interfering (siRNA) to silence MST2, which resulted in increased amounts of p-AKT1 and p-ERK (Figure 5e ). The MST2-silenced cells were then examined by soft agar assays to provide confirmation that the identified target participates in miR-133b-promoted tumorigenesis. Low expression of MST2 protein increased the number of colonies formed by the modified CaSki cells (Figure 5f ). Similarly, the downregulation of MST2 protein in CaSki cells enhanced cell proliferation in 3D cultures (Figure 5g ). These cellular assay results reinforced the view that MST2 is a functional target of suppression by miR-133b during its promotion of cervical carcinoma progression.
A previous report revealed that miR-133 inhibits cardiac hypertrophy through the targeting of two small guanosine triphosphatases, RHOA and CDC42 (Care et al., 2007) . These two genes have also been shown previously to inhibit AKT1 activity (Li et al., 2005) . We confirmed that the protein levels of RHOA and CDC42 are significantly downregulated during the overexpression of miR-133b (Supplementary Figure 6a) . We also independently overexpressed each gene fused with a green fluorescent protein tag in CaSki-miR-133b cells to rescue the effects of miR-133b (Supplementary Figures   S6b and c) . Western blot results showed that the activation of AKT1 by miR-133b was reduced after the overexpression of each gene (Supplementary Figure  S6d) , suggesting that inhibition of these two targets by miR-133b also contributes to the activation of the key AKT1 pathway. Together, these results suggest the operation of a small signaling network in cervical carcinoma cells involving miR-133b, in which miR133b targets MST2, CDC42 and RHOA to activate AKT1 and ERK (Figure 6 ). 
Discussion
The roles of individual miRNAs deregulated in cervical carcinoma have not been studied previously, and in particular the role of an individual miRNA at different stages during cervical cancer progression has not been examined. Our study showed clearly that expressed levels of isoform miR-133b in human cervical carcinoma specimens increased gradually from low levels in normal epithelium to intermediate in carcinoma lesions, and to higher levels in invasive carcinomas. We also confirmed the upregulation of miR-133b directly, in defined cervical carcinoma sections by ISH, and related this elevation to other elevated indicators of cancer cell proliferation and survival such as Ki-67, p-AKT1 and p-ERK activities. Previously reported miRNA profiling studies of cervical carcinoma were limited to global miRNA profiling and found contradictory changes in miR-133 levels in carcinomas compared with normal tissues (Lee et al., 2008; Wang et al., 2008) , without discriminating between the two isoforms of miR-133 and without confirmation of miRNA profiles in patient tissues by ISH. Non-epithelial cells such as muscle found in normal mucosa have high levels of miR-133 (Rao et al., 2006) , and could conceivably contribute to the apparent reduction of miR-133 in relative assays of isolated carcinoma tissues (Lee et al., 2008) .
Each of the different cervical cellular analyses and animal model studies that we undertook confirm that miR-133b promotes cell proliferation and colony formation. It is notable that the tumorigenic functions of miR-133b were also observed with C33A, an HPVfree cervical carcinoma cell line, indicating that miR133b is an independent cellular factor that contributes to cervical oncogenesis. The progressive increase in miR133b levels in patient samples, as the stage and severity of the lesion develops; therefore speaks of an increasing activation of oncogenic processes.
MST2 was identified as a new specific molecular target of miR-133b. MST2 is a known tumor suppressor that inhibits AKT1 phosphorylation and activates the human large tumor suppressor kinase, Lats1 (Chan et al., 2005) . Our results also indicate that MST2 has an important role in cervical tissue to suppress tumor progression through the inhibition of the ERK signaling pathway. Our observations in mice are consistent with a recent report showing that MST2 controls organ size and suppresses tumors by restricting cell proliferation and survival (Song et al., 2010) . Taken together, our findings indicate that elevation of miR-133b deregulates the AKT1 and ERK signaling pathways via direct effects on MST2, CDC42 and RHOA activities, resulting in enhanced cell proliferation and colony formation both in situ and at distant niches, which ultimately promotes tumorigenesis and metastasis ( Figure 6 ).
Whilst we have demonstrated that the elevation of miR-133b likely has an oncogenic role and stimulates progression of cervical carcinoma, a report that miR-133b suppresses colorectal cancer indicates that miR-133b may have other effects in other cell environments. Reports showing miR-133b is downregulated in lung cancer (Crawford et al., 2009) , in head and neck cancer (Liu et al., 2009) , in colorectal cancer and in squamous cell carcinoma of the tongue (Wong et al., 2008) , may suggest other roles in these tissues. Discrimination between the two mature isoforms miR-133a and miR-133b by microarray profiling and hybridization is difficult. Hence, determination of pri-or pre-miRNA levels by RT-PCR methods may better determine the isoform, which is deregulated in these different cancers. Cell models of these cancers also need to be explored in regard to miR-133b effects on cellular functions. MiRNAs could have opposite effects in different tissues as their actions depend on expression of their targets in the particular tissue (Mendell, 2008; Garzon et al., 2009) , and other tissue-specific modulating and regulatory factors may also be required. Indeed, the miR-17-92 cluster has complex pro-and antitumorigenic roles under different cellular conditions (Mendell, 2008) .
It is known that the percentage of spontaneous regression decreases as CIN stages develop (Kahn, 2009 ), yet the reasons are not clear. Our results suggest that the gradual increasing levels of miR-133b from CIN 2 to invasive cervical carcinoma and the strong tumorigenic functions of miR-133b are likely to be a cellular factor contributing to this decreasing regression rate. HPV infection alone is not sufficient for development of a fully malignant cervical cancer (Burk, 1999) , and progression to cervical cancer typically takes >10 years after initial infection (Schiffman and Castle, 2005) . Although a precursor lesion may be suspected upon cytological examination of exfoliated cervical cells and confirmed on histological examination of cervical material, current cytological and histological examinations and HPV DNA test cannot reliably distinguish the women with abnormalities, which will progress to invasive cancer from those whose abnormal lesions will spontaneously regress. Markers that can accurately define substantive disease progression are in great need. We have not examined any potential cellular cause of the progressive increase in miR-133b as CIN stages develop. Any potential relationship between long-term HPV infection and rising miR-133b levels is unknown and was not the subject of this study, but we note that we detected elevated levels of miR-133b in cervical cancer samples, which were both infected with HPV and free of detectable HPV. Overall, our findings do suggest that the progressive elevation of miR-133b levels could be regarded as an independent indicator of the progression of activated cells to develop into cervical cancer. Importantly, the oncogenic effects of miR-133b on the Figure 6 Model of the molecular events related to the upregulation of miR-133b that result in cellular phenotype changes and the development of cervical carcinoma.
promotion of tumorigenesis and metastasis suggest that it should be examined in relation to the prognosis of disease progression.
Materials and methods
Patient samples
Access to patient samples was approved by the human ethics review board of the First Affiliated Hospital of Xinjiang Medical University. All patient samples have signed informed consent by patients for use in research. The clinical stages of cervical cancer tissues were determined by two pathologists independently. Information about the patient samples used in this study is listed in Supplementary Table S1 . Continuously overlapping tissue sections of each sample were used for the analysis of array profiling, RT-PCR, ISH and IHC staining.
MiRNA profiling analysis
Three CIS tissues, two invasive carcinoma tissues and five normal cervical tissues were used for miRNA profiling analysis by microarrays. The cervical carcinoma tissues analyzed contained >90% tumor cells. Purification of total RNA from paraffin-embedded tissue sections was performed as described previously (Varnholt et al., 2008) . The low-molecular-weight RNA was isolated by polyethylene glycol precipitation (Watanabe et al., 2005) . RNA labeling and miRNA profiling analysis were performed, as reported with little modification (Guo et al., 2008) . In brief, the low-molecular-weight RNA was labeled with 5 0 -phosphate-cytidyl-uridyl-Cy3-3 0 (Dharmacon, Chicago, IL, USA) by using T4 RNA ligase (New England Biolabs, Ipswich, MA, USA), and the microarray hybridization reaction was carried out at 50 1C overnight. Each RNA sample was hybridized onto two replicate array slides for reproducibility.
Soft agar assay
Anchorage-independent growth in triplicate 35-mm-diameter dishes was assessed. Cells (2 Â 10 3 ) were distributed on top of 0.8% bottom agar in growth medium and overlaid with 0.4% top agar in growth medium. Colonies growing in soft agar after 4 weeks were stained with 0.2% iodonitrotetrazolium chloride (Sigma, St Louis, MO, USA) and counted.
3D culture cell proliferation assay The 3D culture cell proliferation assays were performed by using the 3D Culture BME Cell Proliferation Assay kit (Trevigen, Gaithersburg, MD, USA), according to manufacturer's instructions. Base membrane extract (35 ml) was added to each well of the 96-well plate and incubated at 37 1C for 1 h to promote gel formation. Cells (2000 cells per well) in 100 ml of culture medium containing 2% base membrane extract were added to each well and incubated at 37 1C for 5-7 days. Cell proliferation reagent (15 ml) was added to each well and incubated at 37 1C for 2 h. Absorbance at 450 nm was recorded.
Mouse experiments
Female SCID mice (4-6-week-old) were used in the xenograft experiments and for experimental metastasis. Each mouse experiment was repeated three times. A total of 5 Â 10 6 CaSki stable cells were injected s.c. into each 4-6-week-old female SCID mouse. Tumor width and length were measured every 3 days, and tumor volumes were calculated. To model metastasis, 2 Â 10 6 SiHa stable cells were injected into each animal via tail vein injection. Three mice of each group were killed at 4 or 6 weeks after injection to monitor the appearance of macrometastasis. All remaining mice were killed at 8 weeks after injection. To clearly observe the metastasis nodules, the lungs were fixed in Bouin's solution (Sigma) displaying lung tissue as brown and metastatic foci as white nodules. Observable metastatic foci on lung surface were counted. The lungs were then embedded in paraffin and the sections were stained with hematoxylin and eosin staining using standard procedures.
To test the influence of miR-133b on tumor initiation, a total of 1 Â 10 7 HK-2-stable cells were injected s.c. into each female BALBc nude mouse. All mice were killed after 2 months to confirm the formation of tumors.
Statistical analysis
Data are presented as mean±s.d. Student's t test was used to compare two groups (Po0.05 was considered significant) unless otherwise indicated (Mann-Whitney U-test). Statistical analysis was performed by using the SPSS software (IBM Corporation, Armonk, NY, USA).
Additional materials and methods are included in the Supplementary Information for this article.
